Basic Information
Incruse Ellipta (previously Incruse)
Regulatory Information
EMEA/H/C/002809
Authorised
April 28, 2014
February 20, 2014
21
March 28, 2025
Company Information
Ireland
12 Riverwalk Citywest Business Campus Dublin 24
GLAXOSMITHKLINE (IRELAND) LIMITED
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Overview Summary
Incruse Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Incruse Ellipta is used for maintenance (regular) treatment. Incruse Ellipta contains the active substance umeclidinium bromide.